Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 10Neoplasms 6Lymphoma, Non-Hodgkin 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Lymphoma 4Leukemia 4Hodgkin Disease 4Burkitt Lymphoma 4Breast Neoplasms 4Vomiting 3Prostatic Neoplasms 3Lymphoma, B-Cell 3Lung Neoplasms 3Leukemia, Hairy Cell 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomatitis 2Stomach Neoplasms 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Myelodysplastic Syndromes 2Mucositis 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

Cyclophosphamide 23blinatumomab 18Cytarabine 16fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Daunorubicin 7Mercaptopurine 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Drug Therapy 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Diphenhydramine × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡